An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Bradykinin (BK) metabolism and its receptors play a central role in drug-induced angioedema (AE) without urticaria through increased vascular permeability. Many cardiovascular and diabetic drugs may cause BK-mediated AE. Angiotensin-converting enzyme inhibitors (ACEIs) and neprilysin inhibitors impair BK catabolism. Dipeptidyl peptidase-IV (DPP-IV) inhibitors reduce the breakdown of BK and substance P (SP). Moreover, angiotensin receptor blockers, thrombolytic agents, and statins may also induce BK-mediated AE. Understanding pathophysiological mechanisms is crucial for preventing and treating drug-induced AE.
Structure of BK and sites of cleavage by significant enzymes related to drug-induced…
Figure 1
Structure of BK and sites of cleavage by significant enzymes related to drug-induced AE. Note: The amino acid sequence of BK is Arginine (Arg)–Proline (Pro)–Proline (Pro)–Glycine (Gly)–Phenylalanine (Phe)–Serine (Ser)–Proline (Pro)–Phenylalanine (Phe)–Arginine (Arg). Figure adapted from [23] for a simplified presentation of the sites of cleavage of BK by different important enzymes, marked with red arrows for ACE (angiotensin-converting enzyme), APP (aminopeptidase P), NEP (neutral endopeptidase), CPN (carboxypeptidase N), and DPPIV (dipeptidyl peptidase IV).
Figure 2
Overall presentation of different causes…
Figure 2
Overall presentation of different causes of angioedema classified by pathophysiology mechanisms, focusing on…
Figure 2
Overall presentation of different causes of angioedema classified by pathophysiology mechanisms, focusing on bradikinergic or BK-mediated angioedema (BK-AE) and drug-induced forms [3,47,109]. * Hereditary angioedema (HAE) with C1-INH deficiency with low antigenic and functional C1-INH levels (HAE-1, 85% of cases), HAE due to C1-INH dysfunction (HAE-2, 10% of cases) characterized by normal or elevated antigenic but low functional C1-INH levels, and HAE with normal C1-INH (HAE-nC1-INH, 5% of cases) due to various gene mutations. ** Acquired forms of BK-AE include drug-induced AE, such as AE induced by angiotensin-converting enzyme inhibitors (ACEIs), AE due to acquired C1-INH deficiency (AAE-C1-INH), and acquired idiopathic non-histaminergic AE. *** Mast cell-mediated angioedema (MC-AE) includes allergic IgE-mediated reactions (such as AE with anaphylaxis), nonallergic non-IgE-mediated reactions (such as AE due to non-steroidal anti-inflammatory drugs or infections), AE in chronic inducible urticaria or chronic spontaneous urticaria (sometimes referred to as idiopathic histaminergic acquired AE). The diversity of mediators involved in MC-AE is reflected also by the fact that patients with chronic spontaneous urticaria may respond to treatment with omalizumab but not to H1 antihistamines.
Figure 3
Metabolism of bradykinin (BK) and…
Figure 3
Metabolism of bradykinin (BK) and angioedema induced by cardiovascular and antidiabetic drugs: angiotesin-converting…
Figure 3
Metabolism of bradykinin (BK) and angioedema induced by cardiovascular and antidiabetic drugs: angiotesin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (sartans), neprilysin inhibitors, direct renin inhibitor (aliskiren), gliptins (DPP-IV inhibitors), and recombinant tissue plasminogen activators (rt-PAs), figure created and adapted after [23,57,87,111].
Bernstein J.A., Moellman J. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int. J. Emerg. Med. 2012;5:39. doi: 10.1186/1865-1380-5-39.
-
DOI
-
PMC
-
PubMed
Mudd P.A., Hooker E.A., Stolz U., Hart K.W., Bernstein J.A., Moellman J.J. Emergency department evaluation of patients with angiotensin converting enzyme inhibitor associated angioedema. Am. J. Emerg. Med. 2020;38:2596–2601. doi: 10.1016/j.ajem.2019.12.058.
-
DOI
-
PubMed
Ferrer M., Rodriguez-Garijo N., Sabate-Bresco M. Medical algorithm: Diagnosis and management of histaminergic angioedema. Allergy. 2023;78:599–602. doi: 10.1111/all.15618.
-
DOI
-
PubMed
Bernstein J.A., Cremonesi P., Hoffmann T.K., Hollingsworth J. Angioedema in the emergency department: A practical guide to differential diagnosis and management. Int. J. Emerg. Med. 2017;10:15. doi: 10.1186/s12245-017-0141-z.
-
DOI
-
PMC
-
PubMed
Long B.J., Koyfman A., Gottlieb M. Evaluation and Management of Angioedema in the Emergency Department. West. J. Emerg. Med. 2019;20:587–600. doi: 10.5811/westjem.2019.5.42650.
-
DOI
-
PMC
-
PubMed